The hardware and bandwidth for this mirror is donated by dogado GmbH, the Webhosting and Full Service-Cloud Provider. Check out our Wordpress Tutorial.
If you wish to report a bug, or if you are interested in having us mirror your free-software or open-source project, please feel free to contact us at mirror[@]dogado.de.
This vignette shows how to transform the deterministic Markov model
presented in vignette("c-homogeneous", "heemod")
in a
probabilistic model.
We will start by re-specifying the deterministic model of HIV therapy
described previously (a monotherapy strategy mono
and
combined therapy strategy comb
).
But instead of defining transition probabilities and state values
directly in define_transition()
or
define_state()
(as in the previous vignette), parameters
will be defined first in a define_parameters()
step. This
is because only parameters defined this way can be resampled in a
probabilistic analysis.
param <- define_parameters(
rr = .509,
p_AA_mono = .721,
p_AB_mono = .202,
p_AC_mono = .067,
p_AD_mono = .010,
p_BC_mono = .407,
p_BD_mono = .012,
p_CD_mono = .250,
p_AB_comb = p_AB_mono * rr,
p_AC_comb = p_AC_mono * rr,
p_AD_comb = p_AD_mono * rr,
p_BC_comb = p_BC_mono * rr,
p_BD_comb = p_BD_mono * rr,
p_CD_comb = p_CD_mono * rr,
p_AA_comb = 1 - (p_AB_comb + p_AC_comb + p_AD_comb),
cost_zido = 2278,
cost_lami = 2086,
cost_A = 2756,
cost_B = 3052,
cost_C = 9007
)
We need to define p_AA_mono
and p_AA_comb
in define_parameters()
because we will need to resample
that value. Only values defined with define_parameters()
can be resampled. So we cannot use the complement alias C
to specify p_AA_comb
in define_transition()
,
as we did before.
mat_trans_mono <- define_transition(
p_AA_mono, p_AB_mono, p_AC_mono, p_AD_mono,
0, C, p_BC_mono, p_BD_mono,
0, 0, C, p_CD_mono,
0, 0, 0, 1
)
mat_trans_comb <- define_transition(
p_AA_comb, p_AB_comb, p_AC_comb, p_AD_comb,
0, C, p_BC_comb, p_BD_comb,
0, 0, C, p_CD_comb,
0, 0, 0, 1
)
State definition remains the same in this example.
state_A <- define_state(
cost_health = 2756,
cost_drugs = dispatch_strategy(
mono = cost_zido,
comb = cost_zido + cost_lami
),
cost_total = discount(cost_health + cost_drugs, .06),
life_year = 1
)
state_B <- define_state(
cost_health = 3052,
cost_drugs = dispatch_strategy(
mono = cost_zido,
comb = cost_zido + cost_lami
),
cost_total = discount(cost_health + cost_drugs, .06),
life_year = 1
)
state_C <- define_state(
cost_health = 9007,
cost_drugs = dispatch_strategy(
mono = cost_zido,
comb = cost_zido + cost_lami
),
cost_total = discount(cost_health + cost_drugs, .06),
life_year = 1
)
state_D <- define_state(
cost_health = 0,
cost_drugs = 0,
cost_total = discount(cost_health + cost_drugs, .06),
life_year = 0
)
Strategies must be first defined and run as in a standard deterministic analysis.
strat_mono <- define_strategy(
transition = mat_trans_mono,
state_A,
state_B,
state_C,
state_D
)
strat_comb <- define_strategy(
transition = mat_trans_comb,
state_A,
state_B,
state_C,
state_D
)
res_mod <- run_model(
mono = strat_mono,
comb = strat_comb,
parameters = param,
cycles = 50,
cost = cost_total,
effect = life_year
)
Now we can define the resampling distributions. The following parameters will be resampled:
Since the log of a relative risk follows a lognormal distribution,
relative risk follows a lognormal distribution whose mean is
rr
and standard deviation on the log scale can be deduced
from the relative risk confidence interval.
\[rr \sim lognormal(\mu = .509, \sigma = .173)\]
Programmed as:
Usually costs are resampled on a gamma distribution, which has the property of being always positive. Shape and scale parameters of the gamma distribution can be calculated from the mean and standard deviation desired in the distribution. Here we assume that mean = variance.
\[cost_A \sim \Gamma(\mu = 2756, \sigma = \sqrt{2756})\]
This can be programmed as:
Proportions follow a binomial distribution that can be estimated by
giving the mean proportion and the size of the sample used to estimate
that proportion with
p_CD ~ binomial(prob = .25, size = 40)
.
Finally multinomial distributions are declared with the number of individuals in each group in the sample used to estimate the proportions. These proportions follow a Dirichlet distribution:
p_AA + p_AB + p_AC + p_AD ~ multinomial(721, 202, 67, 10)
rsp <- define_psa(
rr ~ lognormal(mean = .509, sdlog = .173),
cost_A ~ gamma(mean = 2756, sd = sqrt(2756)),
cost_B ~ gamma(mean = 3052, sd = sqrt(3052)),
cost_C ~ gamma(mean = 9007, sd = sqrt(9007)),
p_CD_mono ~ binomial(prob = .25, size = 40),
p_AA_mono + p_AB_mono + p_AC_mono + p_AD_mono ~ multinomial(721, 202, 67, 10)
)
Now that the distributions of parameters are set we can simply run the probabilistic model as follow:
The average results are computed. In theory these values are more
accurate than simple estimates because of non-linearities. An optional
threshold
can be passed to summary()
to
compute net monetary benefit.
The results of the analysis can be plotted on the cost-effectiveness plane. We can see there seem to be little uncertainty on the costs compared to the uncertainty on the effects, resulting in an uncertainty cloud that looks like a line.
And as cost-effectiveness acceptability curves or EVPI:
plot(pm, type = "ac", max_wtp = 10000, log_scale = FALSE)
plot(pm, type = "evpi", max_wtp = 10000, log_scale = FALSE)
A covariance analysis can be performed on strategy results:
Or on the difference between strategies:
As usual plots can be modified with the standard ggplot2
syntax.
Resampling can be significantly sped up by using parallel computing. This can be done in the following way:
use_cluster()
functions
(i.e. use_cluster(4)
to use 4 cores).close_cluster()
function.Results may vary depending on the machine, but we found speed gains to be quite limited beyond 4 cores.
To compute EVPPI the results can also be exported with
export_savi()
in a format compatible with the SAVI software (Sheffield
Accelerated Value of Information).
The results can be post-processed by the BCEA
package
with the run_bcea()
function.
These binaries (installable software) and packages are in development.
They may not be fully stable and should be used with caution. We make no claims about them.
Health stats visible at Monitor.